logo
logo
Sign in

Stem Cell Therapy is Fastest Growing Segment Fueling Growth of the Global Bile Duct Cancer Market

avatar
Niranjan Mardakar
Stem Cell Therapy is Fastest Growing Segment Fueling Growth of the Global Bile Duct Cancer Market

The global Bile Duct Cancer Market is estimated to be valued at US$ 235.9 Mn in 2023 and is expected to exhibit a CAGR of 12 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Bile duct cancer, also known as cholangiocarcinoma, is a rare cancer that forms in the bile duct. The bile duct carries bile from the liver to the small intestine. Bile helps with digestion and contains waste products. Symptoms of bile duct cancer may include abdominal pain, weight loss, jaundice, and itching. Treatment options include surgery, chemotherapy, radiation therapy, and stem cell therapy.

Market key trends:

One of the key trends in the Global Bile Duct Cancer Market Size is the increasing adoption of stem cell therapy. Stem cell therapy uses stem cells and their derivatives to treat bile duct cancer. Mesenchymal stem cells have shown antitumor effects against cholangiocarcinoma in preclinical studies. They can migrate toward tumor sites and inhibit tumor growth by reducing angiogenesis and inducing tumor cell apoptosis. A few clinical trials are underway to evaluate the safety and efficacy of mesenchymal stem cells in bile duct cancer patients. The promising results from preclinical research have increased focus on stem cell therapy as a viable treatment option for bile duct cancer.

Segment Analysis

The global bile duct cancer market is segmented into papillary carcinoma, adenocarcinoma and others. Among them, adenocarcinoma dominates the market and accounts for around 60% of the total share. This is because adenocarcinoma is the most common type of bile duct cancer, arising from the epithelial cells that line the bile ducts.

Key Takeaways

The global bile duct cancer market is expected to witness high growth, exhibiting a CAGR of 12% over the forecast period, due to increasing incidence of bile duct cancer worldwide.

Regional Analysis

The North America region dominates the bile duct cancer market and is expected to grow at a CAGR of 13% during the forecast period. This is due to the growing prevalence of risk factors such as primary sclerosing cholangitis and rising healthcare expenditure in the region. The Asia Pacific region is expected to showcase the fastest growth over the coming years due to huge patient population and improvement in healthcare facilities.

Key Players

Key players operating in the bile duct cancer market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P. and Delcath Systems, Inc. Incyte Corporation dominates the market owing to its novel pipeline drugs for bile duct cancer treatment in clinical trials.

collect
0
avatar
Niranjan Mardakar
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more